Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Biotechnology developer Cynata Therapeutics (CYP) has raised $15 million through an institutional placement
  • Proceeds will be used to fund the expansion of Cynata’s clinical development pipeline, enhance process development and further regulatory strategy
  • The $15 million institutional placement was offered to new and new investors at 70 cents per new share
  • Healthcare investment firm BioScience Managers led the placement, subscribing to $10 million worth of shares
  • Shares are trading at 75 cents each, down 4.46 per cent following the announcement

Biotechnology developer Cynata Therapeutics (CYP) has raised $15 million through an institutional placement.

Proceeds will be primarily used to fund the expansion of Cynata’s clinical development pipeline, process development and further regulatory strategy.

More specifically, Cynata will undertake further clinical trial designs on multiple unmet medical needs and conditions including, idiopathic pulmonary fibrosis, renal transplantation and diabetic foot ulcers.

The $15 million institutional placement was offered to new and new investors at $0.70 per new share.

A one-for-15 $5.5 million non-renounceable pro-rata entitlement offer will also be offered to eligible shareholders following the placement.

New shares will be allotted December 21.

Cynata Chief Executive and Managing Director Dr Ross Macdonald says the endorsement from BioScience Managers provides validation for the platform.

“The capital secured will enable a logical and significant expansion of our clinical development into new indications, essentially doubling the size of our clinical pipeline,” he commented.

“We look forward to initiating the planned studies in the near term and building on the significant progress made to date with the development of our Cymerus platform technology.”

Shares are trading at 75 cents each, down 4.46 per cent following the announcement.

CYP by the numbers
More From The Market Herald
Alcidion Group (ASX:ALC) - Group Managing Director, Kate Quirke

" Alcidion (ASX:ALC) to raise $55m & acquire Silverlink

Alcidion (ALC) has announced plans to raise $55 million and buy patient software specialists, Silverlink PCS Software.
Actinogen Medical (ASX:ACW) - CEO & Managing Director, Dr Steven Gourlay

" Actinogen Medical (ASX:ACW) partners with Oxford University

Actinogen (ACW) has announced a collaboration with Oxford University researchers to investigate Xanamem and a condition called mild autonomous cortisol secretion (MACS).
Neuren Pharmaceuticals (ASX:NEU) - CEO, Jon Pilcher

" Neuren Pharmaceuticals (ASX:NEU) soars on ‘positive’ Rett syndrome trial results

Neuren Pharmaceuticals’ (NEU) shares have soared following positive top-line results from a phase three study on Rett syndrome.

" Recce Pharmaceuticals (ASX:RCE) spikes amid trial update

Shares in Recce Pharmaceuticals (RCE) have spiked amid a positive update in the clinical trial for the treatment of burn wound infections.